Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA) have officially resolved a long-standing global patent infringement dispute over lipid nanoparticle (LNP) delivery technology, a move that provides Arbutus with a massive liquidity injection while clearing a significant legal hurdle for Moderna’s future commercial operations.
A Financial Turning Point for Arbutus
On July 16, Arbutus secured a definitive victory, receiving approximately $178 million from Moderna—its portion of a $950 million noncontingent settlement payment facilitated by licensee Genevant Sciences. This influx includes legal cost reimbursements, and Arbutus anticipates a further dividend in Q3 from its roughly 16% stake in the parent company of Genevant. Consequently, Arbutus has committed to returning $230 million in capital directly to its shareholders.
The company’s Q1 2026 financial report underscores this shift: revenue skyrocketed to $179.1 million, up from just $1.8 million in the prior-year period, primarily due to the settlement-related licensing income. By aggressively cutting costs and streamlining its workforce, Arbutus reduced operating expenses to $10.2 million. This resulted in a net income of $169.7 million ($0.88 per share), a stark contrast to the $24.5 million net loss reported in Q1 2025. With $95.2 million in cash and liquid assets, the company is now prioritizing its lead hepatitis B candidate, imdusiran, which has secured FDA Fast Track designation.
Moderna’s Aggressive Pipeline Expansion
Moderna continues its evolution from a COVID-19 vaccine manufacturer into a diversified mRNA powerhouse. On August 6, the company reached a major commercial milestone by securing FDA approval for mFLUSIVA, its seasonal influenza vaccine for adults 50 and older—the firm’s fifth approved product. Alongside late-stage programs like the oncology partnership with Merck (intismeran) and the RSV vaccine mRESVIA, Moderna maintains a target of up to 10% revenue growth for 2026.
However, the transition involves significant capital expenditure. Moderna’s Q2 2026 earnings revealed total revenue of $145 million, compared to $142 million in Q2 2025. Operating expenses remained heavy at $960 million, including $651 million directed toward R&D. This resulted in a net loss of $782 million ($1.97 per share). Despite this, Moderna ended the quarter with $6.9 billion in cash and investments, and the company has proactively lowered its full-year 2026 operating expense outlook by $200 million.
Comparative Analysis: Efficiency vs. Scale
The financial profiles of the two companies represent opposing biotech strategies. Arbutus currently demonstrates superior capital efficiency and short-term profitability, utilizing its lean structure to reward shareholders. Conversely, Moderna operates at a massive scale; despite heavy cash burn, its $6.9 billion balance sheet provides the necessary firepower to fund an expansive late-stage pipeline that small-cap competitors cannot replicate.
Market Outlook: The Bull and Bear Cases
For Arbutus, the “bull case” centers on the $230 million capital return, a minimized burn rate, and the potential for an additional $1.3 billion in contingent payouts pending appellate rulings. Critics, however, argue that this profitability is non-recurring, as it relies on legacy intellectual property litigation rather than sustained commercial product sales.
Moderna’s “bull case” is anchored in its commercial infrastructure and the versatility of its mRNA platform, with new products like mFLUSIVA entering the market. The “bear case” focuses on persistent operating losses, occasional pipeline setbacks—such as the recent interim efficacy issues with its norovirus candidate—and the long-term decline of pandemic-era revenue streams.
Institutional Sentiment and Hedge Fund Positioning
Institutional interest has shifted as these companies navigate their post-settlement landscapes. Hedge fund holdings in Arbutus decreased slightly to 25 funds in Q1 2026, down from 27 in the previous quarter. Notable positions include Two Seas Capital, which holds approximately 18.5 million shares, and Whitefort Capital, which maintains a significant 19.81% portfolio allocation in ABUS.
Moderna saw an expansion in institutional participation, with hedge funds increasing to 52 in Q1 2026 from 48. Sophisticated investors, such as Walleye Capital, have utilized hedged strategies—holding both calls and puts—to manage exposure to Moderna’s ongoing regulatory and clinical catalysts.
Ultimately, while Moderna possesses the long-term capital and commercial infrastructure to lead the mRNA sector, Arbutus has successfully demonstrated that aggressive intellectual property defense can generate immediate, tangible value for shareholders, even while its clinical pipeline remains in development.